AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00616603
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.2% ropivacaine injected locally as regional anesthesia given once.
Trial: NCT00616603
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 8mg Dexamethasone injected locally along with ropivacaine for regional anesthesia given once.
Trial: NCT00616603
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2ml(8mg)Dexamethasone given once intravenously.
Trial: NCT01276522
Drug: Canakinumab
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monthly subcutaneous injection with 150mg Canakinumab for 6 months
Trial: NCT01893827
Drug: Oral Naltrexone (O-NTX)
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg pill form of naltrexone taken 1x/day for 6 months.
Trial: NCT03570554
Drug: Acetaminophen ER
RxNorm normalized name: acetaminophen Extended Release Oral Tablet
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3900 mg daily for 3 days, 1300 mg on the fourth day, over-encapsulated extended release (ER) tablet, oral (Treatment B)
Trial: NCT00385775
Drug: AEG35156
RxNorm normalized name: AEG35156
DrugBank: AEG35156 (DB06184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly IV solution infused over 2 hrs
Trial: NCT00191659
Drug: Atomoxetine Hydrochloride
RxNorm normalized name: Atomoxetine Hydrochloride
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00317200
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 90 mg/m2 IV infusion over 1 hour, days 1, 8 and 15 of 28 day cycle.
Trial: NCT00317200
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 10 mg/kg, days 1 and 15 of 28 day cycle
Trial: NCT03563170
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU; Fluorouracil
Trial: NCT02454075
Drug: YF476
RxNorm normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gastrin receptor antagonist
Trial: NCT03563170
Drug: nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ABRAXANE® \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]
Trial: NCT03563170
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NEXAVAR® tablets, for oral use
Trial: NCT01642485
Drug: Moxifloxacin 400 mg fasted
RxNorm normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects receiving drug (400 mg moxifloxacin),having fasted overnight for 10 hours.~This is the standard probe for the assessment of assay sensitivity in Thorough QT (TQT) studies.
Trial: NCT01642485
Drug: Moxifloxacin 400 mg fed
RxNorm normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Currently, there is no published data showing the effects of a single 400 mg oral dose of moxifloxacin on the ECG/QT/QTc after food.
Trial: NCT03776071
Drug: Enzastaurin Hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mg
Trial: NCT03776071
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: mg/m\^2
Trial: NCT03042871
Drug: 0.5mg intravitreal ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerland) via a pars plana transcleral injection through 30-gauge needle at 3.5 to 4mm of inferotemporal limbus. Levofloxacin eye drops ( Cravit Eye Drops, Santen, Japan) was instilled 4 times a day in the study eye before the treatment at least 1 day. Povidone-iodine (5%, Luofushan Pharmaceutical Co., China) was applied to the conjunctiva bulbi and the fornices for at least 3 minutes before injection. Patients were instructed to continue the levofloxacin eye drops 4 times a day for 3 days
Trial: NCT03563170
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ERBITUX® injection, for IV infusion)
Trial: NCT02697136
Drug: CER-001
RxNorm normalized name: CER-001
DrugBank: CER-001 (DB18538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human apoA-I/phospholipid complexes
Trial: NCT02245620
Drug: Elamipretide
RxNorm normalized name: Elamipretide
DrugBank: Elamipretide (DB11981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elamipretide 0.25 mg/kg/hour administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours
Trial: NCT04372706
Drug: RTX-240
RxNorm normalized name: RTX
DrugBank: Resiniferatoxin (DB06515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engineered red cells co-expressing 4-1BBL and IL-15TP
Trial: NCT04372706
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Humanized immunoglobulin G4 programmed death receptor-1 blocking antibody
Trial: NCT00901784
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25mg Tablets
Trial: NCT01191203
Drug: Copper IUD
RxNorm normalized name: COPPER IUD (PARAGARD T380A)
DrugBank: Copper (DB09130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper IUD (CuT360)
Trial: NCT01087840
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Raltegravir tablet 400mg is taken orally, twice daily with or without food for 28 days along with Tenofovir disoproxil fumarate/emtricitabine 300mg/200mg 1 tablet taken orally once daily with or without food for 28 days.~Arms: Raltegravir/Truvada Other Names: Isentress/Truvada
Trial: NCT03596775
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Children in Dexmedetomidine group receive intravenous dexmedetomidine 0.5 ug/kg over 10 minutes after induction of anesthesia.
Trial: NCT01191203
Drug: Depo Medroxyprogesterone acetate
RxNorm normalized name: medroxyprogesterone Injection [Depo-Provera]
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DMPA 150 mg IM q 3 months
Trial: NCT01316770
Drug: Dexamethasone Parotid Irrigation
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irrigation of the parotid gland from one side of the mouth with dexamethasone.
Trial: NCT02106585
Drug: JTT-251 or Placebo
RxNorm normalized name: JTT-251
DrugBank: JTT-251 (DB18174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive JTT-251 or Placebo
Trial: NCT03857230
Drug: Follitropin alfa (Primapur)
RxNorm normalized name: Follitropin Alfa
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur.
Trial: NCT03857230
Drug: Follitropin alfa (Gonal-F)
RxNorm normalized name: Follitropin Alfa
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur.
Trial: NCT00909428
Drug: Solifenacin Succinate
RxNorm normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants take 10mg daily solifenacin succinate for 30 days
Trial: NCT03596775
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children in Control Comparator group receive intravenous saline 10ml over 10 minutes after induction of anesthesia.
Trial: NCT01765023
Drug: Period I : atorvastatin, Period II : atorvastatin and metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01765023
Drug: Period I : metformin, Period II : atorvastatin and metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00035256
Drug: teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00035256
Drug: raloxifene HCl
RxNorm normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01420679
Drug: Pralatrexate Injection
RxNorm normalized name: pralatrexate Injection
DrugBank: Pralatrexate (DB06813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous (IV) push administration over 30 seconds to 5 minutes via a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 30 mg/m2~Administered weekly for 3 weeks of a 4-week cycle until criteria for discontinuation per the protocol are met.
Trial: NCT02616315
Drug: Naltrexone HCl/Bupropion HCl Placebo
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone/bupropion placebo-matching tablets
Trial: NCT02616315
Drug: Naltrexone HCl/Bupropion HCl
RxNorm normalized name: naltrexone HCl/bupropion HCl 8 mg-90 mg ORAL TABLET, EXTENDED RELEASE
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone HCl 8 mg/bupropion HCl 90 mg tablets
Trial: NCT03412188
Drug: Eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients who showed no response (platelet count ≤ 20x109/L) initially for 3 months or relapse after 6 months after at least one prior ITP therapy will receive a total daily dose of eltrombopag of (25-50mg/d)
Trial: NCT03412188
Drug: conventional
RxNorm normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who are currently receiving conventional lines of treatment (steroids, IVIG, azathioprine, and rituximab, Mycophenolate mofetil) will continue on the same line of treatment
Trial: NCT03284645
Drug: Tenofovir Disoproxil Fumarate (TDF) 300 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg
RxNorm normalized name: efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG [Symfi]
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of 300 mg TDF, 300 mg 3TC and 600 mg EFV taken once daily.
Trial: NCT03284645
Drug: Abacavir (ABC) 600 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg
RxNorm normalized name: abacavir 600 MG / lamivudine 300 MG [Epzicom]
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of 600 mg ABC, 300 mg 3TC and 600 mg EFV taken once daily.
Trial: NCT03284645
Drug: Zidovudine (AZT) 300 mg + Lamivudine (3TC) 150 mg twice daily + Efavirenz (EFV) 600 mg once daily
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of 300 mg AZT and 150 mg 3TC taken twice daily, plus 600 mg EFV taken once daily.
Trial: NCT00412594
Drug: Cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00090727
Drug: AQ4N
RxNorm normalized name: Tirapazamine
DrugBank: Tirapazamine (DB04858)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02340611
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polyadenosine 5'diphosphoribose polymerase (PARP) Inhibitor
Trial: NCT02340611
Drug: Cediranib
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor that is a potent inhibitor of all three VEGF receptors (VEGFR-1, -2 and -3)
Trial: NCT04076371
Drug: olanzapine-sertraline combination
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)
Trial: NCT04076371
Drug: only olanzapine
RxNorm normalized name: Product containing only olanzapine (medicinal product)
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)
Trial: NCT04076371
Drug: risperidone-sertraline combination
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)
Trial: NCT04076371
Drug: only risperidone
RxNorm normalized name: Product containing only risperidone (medicinal product)
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)
Trial: NCT04076371
Drug: paliperidone-sertraline combination
RxNorm normalized name: Paliperidone
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)
Trial: NCT04076371
Drug: only paliperidone
RxNorm normalized name: Product containing only paliperidone (medicinal product)
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)
Trial: NCT04076371
Drug: ziprasidone-sertraline combination
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)
Trial: NCT04076371
Drug: only ziprasidone
RxNorm normalized name: Product containing only ziprasidone (medicinal product)
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)
Trial: NCT02255006
Drug: Euglucon 5mg
RxNorm normalized name: manganese gluconate 5 MG
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 healthy volunteers are administered 5 mg of glibenclamide (Euglucon, Roche Pharma) 3 hour before FMD measurement. This dosage has previously been shown to be able to completely inhibit forearm KATP channels. With the glibenclamide administration, a 10% dextrose infusion is started and titrated to maintain blood sugar levels between 80 and 120 mg/dL throughout the study period. 3 hours after glibenclamide administration, the subjects undergo FMD measurement before and after ischemia reperfusion injury. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method.
Trial: NCT01099774
Drug: Bimatoprost 0.03% Ophthalmic Solution
RxNorm normalized name: Bimatoprost 0.03% Ophthalmic Solution
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One drop administered in each eye, every evening, for 12 weeks
Trial: NCT02064465
Drug: Lamotrigine Dispersible/Chewable tablet
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of lamotrigine dispersible/chewable 100mg tablet at Day1
Trial: NCT02064465
Drug: Lamotrigine Compressed tablet
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of lamotrigine compressed 100mg tablet at Day1
Trial: NCT00791830
Drug: Irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 300 mg \* 1 daily, 1 year
Trial: NCT00791830
Drug: Placebo matching irbesartan 150 mg
RxNorm normalized name: irbesartan 150 MG
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 300 mg \* 1 daily, 1 year
Trial: NCT02255006
Drug: Celebrex 200mg
RxNorm normalized name: Celebrex 200mg Capsule
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 healthy volunteers are administered celecoxib, a selective COX-2 inhibitor, 200 mg twice daily for 5 days. Last dose of celecoxib is administered at morning. Volunteers undergo FMD measurements before and after ischemia reperfusion injury in that morning of last dose of celecoxib. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method
Trial: NCT01733043
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02645552
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 1 gram in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
Trial: NCT00889473
Drug: Larazotide acetate
RxNorm normalized name: Larazotide
DrugBank: Larazotide (DB05645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gelatin capsule
Trial: NCT02232152
Drug: 6,8-bis(benzylthio)octanoic acid
RxNorm normalized name: 6,8-bis(benzylthio)octanoic acid
DrugBank: Devimistat (DB12109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00162175
Drug: Muraglitazar
RxNorm normalized name: Muraglitazar
DrugBank: Muraglitazar (DB06510)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05040620
Drug: Olive Oil Topical Oil
RxNorm normalized name: olive oil TOPICAL OIL (ML)
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the effect of olive oil local application in decreasing orthodontic alighment phase
Trial: NCT02998476
Drug: Parsaclisib
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parsaclisib once daily for 8 weeks followed by once weekly
Trial: NCT01752894
Drug: Keep DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maintain DAPT for 12 months according to level of uncovered strut (\>6%) at 3months OCT follow up after stent implantation.
Trial: NCT01752894
Drug: Discontinue DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: discontinue DAPT according to level of uncovered strut (≤6%) at 3months OCT follow up after stent implantation.
Trial: NCT00033657
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Days 1 - 35 : Cisplatin 30 mg/m² days 1, 8, 15, 22, 29~Days 63 - 77 : cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles
Trial: NCT00033657
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days 1 - 35 : Irinotecan 65 mg/m² days 1, 8, 22, 29~Days 63 - 77 : irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles
Trial: NCT00033657
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Days 1 - 35 : Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29~Days 63 - 77 : paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles
Trial: NCT00630084
Drug: pegylated interferon alpha 2a and plus ribavirin
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
Trial: NCT03037736
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil is an antimetabolite that is commonly used in glaucoma surgery to prevent postoperative scaring.
Trial: NCT03037736
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab is an anti-VEGF antibody that is commonly used to prevent or treat neovascularization in retinal disorders.
Trial: NCT03337594
Drug: Pre-operative MRI with Dotarem
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dotarem® (gadoterate meglumine - Guerbet)
Trial: NCT03337594
Drug: Pre-operative MRI with MultiHance
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MultiHance® (gadobenate dimeglumine - Bracco)
Trial: NCT00199329
Drug: ondansetron adding in PCA
RxNorm normalized name: lauryl PCA
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00392522
Drug: 50% Nitrous Oxide and 50% Oxygen (MEOPA)
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no